WALTHAM,
Mass., March 6, 2023 /PRNewswire/ -- Syndax
Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage
biopharmaceutical company developing an innovative pipeline of
cancer therapies, today announced that on March 1, 2023 the Company granted an inducement
award to purchase up to 15,200 shares of common stock to one new
employee under the Company's 2023 Inducement Plan. The stock option
has an exercise price per share of $24.86, the closing price
of the Company's common stock on the Nasdaq Global Select Market
on March 1, 2023 and will vest over four years, with 25%
of the underlying shares vesting on the one-year anniversary of the
vesting commencement date and 1/48th of the underlying shares
vesting monthly thereafter over 36 months, subject to the
employee's continued service relationship with Syndax through the
applicable vesting dates.
About Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals is a clinical stage
biopharmaceutical company developing an innovative pipeline of
cancer therapies. Highlights of the Company's pipeline include
revumenib, a highly selective inhibitor of the Menin–KMT2A binding
interaction, and axatilimab, a monoclonal antibody that blocks the
colony stimulating factor 1 (CSF-1) receptor, both currently in
pivotal trials. For more information, please
visit www.syndax.com or follow the Company on Twitter and
LinkedIn.
Syndax Contact
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827
SNDX-G
View original
content:https://www.prnewswire.com/news-releases/syndax-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-301763791.html
SOURCE Syndax Pharmaceuticals, Inc.